Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Bottom Line: A Src inhibitor saracatinib impaired growth in cell lines that are insensitive to both Met and FGFR2 inhibitors.Saracatinib also effectively impaired peritoneal dissemination of Met-independent and FGFR2-independent SGC cells.Moreover, DGC cell lines exhibited nearly mutually exclusive susceptibility to Met, FGFR and Src inhibitors.
Affiliation: Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We first examined protein tyrosine phosphorylation in a panel of gastric cancer cell lines (Table S1) by immunoblotting with an anti-phosphotyrosine antibody 4G10 (Fig.1a). The amount of phosphotyrosine-containing proteins mainly distributed from 37 to 250 kDa was greatly elevated in several DGC cell lines, including MKN45, KATO-III, 58As1, 58As9 and SNU-5. Other cell lines exhibited moderate or only a modest level of tyrosine-phosphorylated proteins. Notably, the band pattern of phosphotyrosine-containing proteins in DGC cell lines, which apparently varied among lines, was significantly distinct from those in differentiated gastric cancer cells. These observations indicate that DGC display specific activation of some intracellular signaling pathways involving tyrosine phosphorylation.
Affiliation: Division of Metastasis and Invasion Signaling, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan.